Subscribe: Ganfyd - Recent changes [en]
http://ganfyd.org/index.php?title=Special:Recentchanges&feed=rss&submit=Read
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
health  line line  line  older revision  public health  ref  revision december  revision revision  revision  small  ← older 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Ganfyd - Recent changes [en]

Ganfyd - Recent changes [en]



Track the most recent changes to the wiki in this feed.



Last Build Date: Fri, 15 Dec 2017 17:11:04 GMT

 



Help talk:Contribute

Fri, 15 Dec 2017 16:28:32 GMT

← Older revision Revision as of 16:28, 15 December 2017
Line 4: Line 4:
Thank you![[User:Apothecary|Apothecary]] 19:43, 3 April 2008 (BST)
Thank you![[User:Apothecary|Apothecary]] 19:43, 3 April 2008 (BST)
 +
 +
===Registration link is broken===
 +
The link http://ganfyd.net/register/register.php appears to be broken. How can people register to become new editors, please?
 +
 +
--[[User:Penglish|Penglish]] 16:28, 15 December 2017 (UTC)



Mepolizumab

Thu, 14 Dec 2017 08:40:19 GMT

is licensed now ← Older revision Revision as of 08:40, 14 December 2017 (One intermediate revision not shown)Line 1: Line 1: ==Introduction== ==Introduction== Humanised IgG1 monoclonal antibody against [[interleukin-5]]. Used in the treatment of [[hypereosinophilic syndrome]] (HES). Humanised IgG1 monoclonal antibody against [[interleukin-5]]. Used in the treatment of [[hypereosinophilic syndrome]] (HES). -{{PharmacologyBox||Bosatria®|[[image:{{PAGENAME}}Molecule.png|thumb|{{PAGENAME}} Molecule]]|[[image:{{PAGENAME}}.png|center]]|||}} It also appears in those with raised [[eosinophil]] counts to be effective in reducing the frequency of exacerbations of [[COPD]] .+{{PharmacologyBox||Bosatria®, Nucala®|[[image:{{PAGENAME}}Molecule.png|thumb|{{PAGENAME}} Molecule]]|[[image:{{PAGENAME}}.png|center]]|||}} It also appears in those with raised [[eosinophil]] counts to be effective in reducing the frequency of exacerbations of [[COPD]] or in severe [[asthma]][https://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=29118815  Pouliquen IJ, Howarth P, Austin D, Gunn G, Meyer E, Price RG, Bradford E. Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology. 2017 ; 13:45.](Electronic-eCollection) ([http://dx.doi.org/10.1186/s13223-017-0217-6 Link to article] – subscription may be required.). [[Category:medicines]] [[Category:medicines]] ==Clinical Use== ==Clinical Use== ===Indications=== ===Indications===  +*[[eosinophilic granulomatosis with polyangiitis]] ===Administration=== ===Administration=== ''IV'' or ''s/c'' ''IV'' or ''s/c'' Line 14: Line 15: ===Special advice=== ===Special advice=== ==Pharmacology==   ==Pharmacology==   -{{draft}}+{{refsec}} [[Category: Monoclonal antibodies]] [[Category: Monoclonal antibodies]] [[Category: Therapeutic antibody]] [[Category: Therapeutic antibody]] [[Category: Medicines]] [[Category: Medicines]] -[[Category:Unlicensed medicines - EU]]  [...]



Atrigel

Thu, 14 Dec 2017 08:32:36 GMT

Created page with "{{PharmacologyBox}} A patented sub cutaneous medicine delivery system using biodegradable polymers dissolved in a biocompatible carrier. It is used as a way of sustained release ..."

New page

{{PharmacologyBox}}
A patented sub cutaneous medicine delivery system using biodegradable polymers dissolved in a biocompatible carrier. It is used as a way of sustained release of a product such as:
*[[leuprolide]]
*[[risperidone]]
*[[doxycycline]]
It might also be used for vaccines.



Risperidone

Thu, 14 Dec 2017 08:26:17 GMT

update

← Older revision Revision as of 08:26, 14 December 2017
Line 1: Line 1:
-
{{PharmacologyBox|Risperidone|Risperdal®
+
{{PharmacologyBox|Risperidone|Risperdal®, RBP-7000®
|[[image:RisperidoneMolecule.png|thumb|Risperidone Molecule]]|[[image:Risperidone.png|centre]]|[[CYP2D6]]|dopamine receptor blockade etc|}}
|[[image:RisperidoneMolecule.png|thumb|Risperidone Molecule]]|[[image:Risperidone.png|centre]]|[[CYP2D6]]|dopamine receptor blockade etc|}}
[[Category:Medicines]][[Category:Atypical antipsychotics]]
[[Category:Medicines]][[Category:Atypical antipsychotics]]
Line 6: Line 6:
*[[Bipolar affective disorder|Mania]]
*[[Bipolar affective disorder|Mania]]
===Administration===
===Administration===
 +
*Oral
 +
*S/C ([[Atrigel]]® delivery system)
====Dose====
====Dose====
*Psychosis: 2mg in 1-2 doses on day 1, then 4mg in 1-2 doses on day 2. usual dose 4-6 mg daily (max 16mg)
*Psychosis: 2mg in 1-2 doses on day 1, then 4mg in 1-2 doses on day 2. usual dose 4-6 mg daily (max 16mg)



Sotaglifozin

Wed, 13 Dec 2017 21:24:49 GMT

categorise

New page

{{PharmacologyBox||LX4211|[[image:{{PAGENAME}}Molecule.png|thumb|{{PAGENAME}} Molecule]]|[[image:{{PAGENAME}}.png|center]]|||}}
==Introduction==
[[Sotaglifozin]] is an oral inhibitor of [[Sodium/glucose cotransporter 1|sodium-glucose cotransporters 1]] and [[Sodium-glucose cotransporter 2|2]] in development to treat [[diabetes mellitus]][https://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=23630033 Lapuerta P, Rosenstock J, Zambrowicz B, Powell DR, Ogbaa I, Freiman J, Cefalu WT, Banks P, Frazier K, Kelly M, Sands A. Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy. Clinical cardiology. 2013 Jul; 36(7):367-371.](Print-Electronic) ([http://dx.doi.org/10.1002/clc.22125 Link to article] – subscription may be required.). Use in Type 1 diabetes may be limited due to the increase in [[ketoacidosis]] from 2.4% to 8.6% in 24 weeks therapy[https://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=28899222 Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, Pozzilli P, Gesty-Palmer D, Lapuerta P, Simó R, Danne T, McGuire DK, Kushner JA, Peters A, Strumph P. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. The New England journal of medicine. 2017 Sep.](Print-Electronic) ([http://dx.doi.org/10.1056/nejmoa1708337 Link to article] – subscription may be required.).
==Clinical Use==
===Indications===
===Administration===
''Oral''400mg daily (adults)
==Clinical Issues==
===Contra-indications===
===Cautions and Interactions===
===Side effects===
*[[hypoglycaemia]]
*[[Ketoacidosis]]

===Special advice===
==Pharmacology==
{{refsec}}
[[Category:SGLT2 inhibitors]]
[[Category:Oral hypoglycaemic agents]]



Congenital glucose/galactose malabsorption

Wed, 13 Dec 2017 21:13:25 GMT

subclude

New page

{{GeneticsBox}}
[[Category:Genetic syndromes]]
{{:SLC5A1}}
[[Category:Metabolic disorders]]



Sodium/glucose cotransporter 1

Wed, 13 Dec 2017 21:11:36 GMT

typo

← Older revision Revision as of 21:11, 13 December 2017
Line 1: Line 1:
-
{{BiochemistryBox|||Sodium-glucose cotransporter 2, High affinity sodium-glucose cotransporter, solute carrier family 5 member 1, Na(+)/glucose cotransporter 1}}
+
{{BiochemistryBox|||Sodium-glucose cotransporter 1, High affinity sodium-glucose cotransporter, solute carrier family 5 member 1, Na(+)/glucose cotransporter 1}}
{{:SLC5A1}}
{{:SLC5A1}}
[[Category:Membrane proteins]]
[[Category:Membrane proteins]]
[[Category:Sodium:solute symporters]]
[[Category:Sodium:solute symporters]]



Sodium-glucose cotransporter 1

Wed, 13 Dec 2017 21:11:18 GMT

redirect

New page

#redirect[[Sodium/glucose cotransporter 1]]



Sodium/glucose cotransporter 1

Wed, 13 Dec 2017 21:10:02 GMT

subclude

New page

{{BiochemistryBox|||Sodium-glucose cotransporter 2, High affinity sodium-glucose cotransporter, solute carrier family 5 member 1, Na(+)/glucose cotransporter 1}}
{{:SLC5A1}}
[[Category:Membrane proteins]]
[[Category:Sodium:solute symporters]]



SLC5A1

Wed, 13 Dec 2017 21:06:49 GMT

for subclusion

New page


{{GeneticsBox|||NAGT, SGLT1}}
[[Category:Genes]]

The [[SLC5A1]] gene at 22q12.3 codes for the 664 amino acid [[sodium/glucose cotransporter 1]]. This actively transports glucose into cells with Na+ cotransport in a ratio of two Na+ to one [[glucose]] molecule. In the human kidney sodium/glucose cotransporters are arranged in series along kidney [[proximal tubule]]s.

Dysfunctional mutations cause [[congenital glucose/galactose malabsorption]] (GGM, {{OMIM|606824}}) with severe diarrhoea and dehydration which are usually fatal in the first few weeks of life unless [[glucose]] and [[galactose]] are eliminated from the diet.



Stereotatic body radiation therapy

Wed, 13 Dec 2017 20:50:38 GMT

definition

New page

{{SubjectBox}}
Stereotatic body radiation therapy (SBRT) is any radiotherapy technique in which accurate 3D positional data obtained from say CT scans is used to direct radiation beams so that tissue damage outside the field of interest is limited. As of 2017 state of the art technology can deliver to even moving (eg heart) target volumes of a few mls with safe (non necrosing) radiation doses delivered to other nearby organs.
[[Category:Radiotherapy]]



Cardiac ablation

Wed, 13 Dec 2017 20:40:05 GMT

de redirect ← Older revision Revision as of 20:40, 13 December 2017 Line 1: Line 1: -#redirect[[Pulmonary vein ablation]]+Cardiac ablation is one of a number of techniques in which undesired conduction pathways in cardiac tissue are destroyed. It is usually done invasively by percutaneous cardiac [[catheter ablation]] using cryotherapy or radiofrequency therapy. Surgery can also be appropriate. Non invasive techniques also exist using radiotherapy which may have a higher success and lower complication rate. Types are:  +*[[Pulmonary vein ablation]] for [[atrial fibrillation]]/[[atrial flutter]] eg:  +**Right atrial [[catheter ablation]]  +**Pulmonary vein [[radiofrequency catheter ablation]]  +**Pulmonary vein [[cryoablation]]  +*Cardiac [[percutaneous catheter ablation]] for other arrhythmias (eg [[ventricular tachycardia]])  +*Cardiac [[stereotatic body radiation therapy]] (SBRT)[https://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=27996023  Lehmann HI, Graeff C, Simoniello P, Constantinescu A, Takami M, Lugenbiel P, Richter D, Eichhorn A, Prall M, Kaderka R, Fiedler F, Helmbrecht S, Fournier C, Erbeldinger N, Rahm AK, Rivinius R, Thomas D, Katus HA, Johnson SB, Parker KD, Debus J, Asirvatham SJ, Bert C, Durante M, Packer DL. Feasibility Study on Cardiac Arrhythmia Ablation Using High-Energy Heavy Ion Beams. Scientific reports. 2016 Dec; 6:38895.](Electronic) ([http://dx.doi.org/10.1038/srep38895 Link to article] – subscription may be required.) [[category:cardiology]] [[category:cardiology]]  +[[Category:Cardiac electrophysiology]] [...]



Arrhythmias

Wed, 13 Dec 2017 20:23:21 GMT

treatments

← Older revision Revision as of 20:23, 13 December 2017
Line 17: Line 17:
*[[Brugada syndrome]]
*[[Brugada syndrome]]
-
 
+
==Treatment==
 +
This is usually done (there are specific indications for each treatment) with:
 +
*[[:Category:Anti-arrhythmics|Anti-arrhythmic medicines]]
 +
*Clinical manoeuvre such as [[carotid sinus massage]]
 +
**[[Chemical cardioversion]]
 +
*[[Electrical cardioversion]] or [[defibrillation]]
 +
*[[Cardiac pacemaker]]
 +
*[[Implantable cardioverter defibrillator]]
 +
*[[Cardiac ablation]]
[[Category: Cardiology]][[Category:Cardiac electrophysiology]]
[[Category: Cardiology]][[Category:Cardiac electrophysiology]]



Category:Class Ic anti-arrhythmics

Wed, 13 Dec 2017 20:18:59 GMT

categorise

← Older revision Revision as of 20:18, 13 December 2017
Line 1: Line 1:
-
[[Category:Drug classes]][[Category:Anti-arrhythmics]]
+
[[Category:Cardiac electrophysiology]]
 +
[[Category:Cardiology]][[Category:Drug classes]][[Category:Anti-arrhythmics]]



Category:Class Ib anti-arrhythmics

Wed, 13 Dec 2017 20:18:42 GMT

categorise

← Older revision Revision as of 20:18, 13 December 2017
Line 1: Line 1:
[[Category:Drug classes]][[Category:Anti-arrhythmics]]
[[Category:Drug classes]][[Category:Anti-arrhythmics]]
 +
[[Category:Cardiac electrophysiology]]
 +
[[Category:Cardiology]]



Category:Class Ia anti-arrhythmics

Wed, 13 Dec 2017 20:18:23 GMT

categorise

← Older revision Revision as of 20:18, 13 December 2017
Line 1: Line 1:
[[Category:Drug classes]][[Category:anti-arrhythmics]]
[[Category:Drug classes]][[Category:anti-arrhythmics]]
 +
[[Category:Cardiac electrophysiology]]
 +
[[Category:Cardiology]]



Category:Class IV anti-arrhythmics

Wed, 13 Dec 2017 20:17:53 GMT

categorise

← Older revision Revision as of 20:17, 13 December 2017
Line 6: Line 6:
[[Category:Anti-arrhythmics]]
[[Category:Anti-arrhythmics]]
[[Category:Calcium channel blockers]]
[[Category:Calcium channel blockers]]
 +
[[Category:Cardiac electrophysiology]]
 +
[[Category:Cardiology]]



Category:Class III anti-arrhythmics

Wed, 13 Dec 2017 20:17:15 GMT

categorise

← Older revision Revision as of 20:17, 13 December 2017
Line 1: Line 1:
These predominantly block the potassium (K+) efflux channel. See [[Vaughan Williams antiarrhythmic classification]]
These predominantly block the potassium (K+) efflux channel. See [[Vaughan Williams antiarrhythmic classification]]
[[Category:Drug classes]][[Category:Cardiology]][[Category:Anti-arrhythmics]]
[[Category:Drug classes]][[Category:Cardiology]][[Category:Anti-arrhythmics]]
 +
[[Category:Cardiac electrophysiology]]



Category:Anti-arrhythmics

Wed, 13 Dec 2017 20:16:58 GMT

categorise

← Older revision Revision as of 20:16, 13 December 2017
Line 1: Line 1:
[[Category:Drug classes]]
[[Category:Drug classes]]
 +
[[Category:Cardiac electrophysiology]]
 +
[[Category:Cardiology]]



Defibrillator

Wed, 13 Dec 2017 20:15:06 GMT

wikify

← Older revision Revision as of 20:15, 13 December 2017
Line 15: Line 15:
*[[ECG]]
*[[ECG]]
*[[DC cardioversion]]
*[[DC cardioversion]]
-
 
+
*[[Implantable cardioverter defibrillator]]
{{refsec}}
{{refsec}}



Cardiac pacemaker

Wed, 13 Dec 2017 20:12:06 GMT

categorise

← Older revision Revision as of 20:12, 13 December 2017
Line 31: Line 31:
{{Draft}}
{{Draft}}
-
 
+
[[Category:Cardiac electrophysiology]]
[[Category: Physiology]]
[[Category: Physiology]]
[[Category:Cardiology]]
[[Category:Cardiology]]



Chemical Cardioversion

Wed, 13 Dec 2017 20:08:12 GMT

moved [[Chemical Cardioversion]] to [[Chemical cardioversion]] standard wiki page titles is non capitalisation




Abbreviations

Tue, 12 Dec 2017 14:36:48 GMT

N: ← Older revision Revision as of 14:36, 12 December 2017 (One intermediate revision not shown)Line 567: Line 567: *NIV - [[Non-invasive ventilation]] *NIV - [[Non-invasive ventilation]] *NHS - [[National Health Service]] *NHS - [[National Health Service]] -*NHS with strikethrough - used in a box in [[BNF] to mean ''"not prescribable under National Health Service (NHS)"''.+*NHS (NHS with strikethrough) - used in a box in [[BNF]] to mean ''"not prescribable under National Health Service (NHS)"''. *NHS24 - [[Scotland]]'s [[Out of Hours]] Service *NHS24 - [[Scotland]]'s [[Out of Hours]] Service *NLH - [[National library for health|National Library for Health]] *NLH - [[National library for health|National Library for Health]] Line 581: Line 581: *NSVT - Non-Sustained [[ventricular tachycardia|Ventricular Tachycardia]] *NSVT - Non-Sustained [[ventricular tachycardia|Ventricular Tachycardia]] *NTHi - [[Haemophilus influenzae|Non-typable ''Haemophilus influenzae'']] *NTHi - [[Haemophilus influenzae|Non-typable ''Haemophilus influenzae'']]  +*NTTB - [[Diphtheria|Non-Toxigenic Toxin gene Bearing (NTTB) ''C. diphtheriae'']] *nvCJD - [[Creutzfeldt-Jakob disease|New Variant Creutzfeldt-Jakob disease]] *nvCJD - [[Creutzfeldt-Jakob disease|New Variant Creutzfeldt-Jakob disease]] *NWC - Nurse With Clipboard - see [https://www.doctors.net.uk/Forum/viewPost.aspx?post_id=3450566&forum_id=1 DNUK thread (members only)] *NWC - Nurse With Clipboard - see [https://www.doctors.net.uk/Forum/viewPost.aspx?post_id=3450566&forum_id=1 DNUK thread (members only)] [...]



Diphtheria

Tue, 12 Dec 2017 14:31:33 GMT

Aetiology: ← Older revision Revision as of 14:31, 12 December 2017 (2 intermediate revisions not shown)Line 2: Line 2: ==Introduction== ==Introduction== ==Aetiology== ==Aetiology== -Diphtheria is caused by ''[[Corynebacterium diphtheriae]]'', a Gram positive bacillus.+{{QuotationBox|Respiratory or cutaneous diphtheria is caused by toxigenic strains of ''C. diphtheriae'' and ''C. ulcerans'', and, very rarely, ''C. pseudotuberculosis''. ''C. diphtheriae'' is a non-sporing, nonencapsulated, and non-motile Gram positive bacillus (8). Four biovars of C. diphtheriae can be distinguished biochemically: gravis, intermedius, mitis, and belfanti (9). In the United Kingdom (UK), most infections in recent years have been caused by biovar mitis (around 80%) followed by biovar gravis (7). The clinical and public health management is identical for all toxigenic strains.|[https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/416108/Diphtheria_Guidelines_Final.pdf PHE Diphtheria guidance.]}} ==Epidemiology== ==Epidemiology== Line 29: Line 29: [[Notifiable diseases|Statutorily notifiable]] [[Notifiable diseases|Statutorily notifiable]] == External links == == External links ==  +*[https://www.gov.uk/government/publications/diphtheria-public-health-control-and-management-in-england-and-wales PHE guidance on the public health management of diphtheria in England and Wales][https://www.gov.uk/government/publications/diphtheria-public-health-control-and-management-in-england-and-wales 1. Brown C, Diphtheria Guidelines Working Group. ''Public health control and management of diphtheria (in England and Wales).'' London: Public Health England, 2015(24 March).]  + {{draft}} {{draft}} [...]



CCDC

Tue, 12 Dec 2017 11:03:13 GMT

← Older revision Revision as of 11:03, 12 December 2017 (2 intermediate revisions not shown)Line 1: Line 1: [[Category: Infectious diseases]][[Category: Health protection]] [[Category: Public health]]{{stub}} [[Category: Infectious diseases]][[Category: Health protection]] [[Category: Public health]]{{stub}} CCDC - Consultant in Communicable Disease Control. (Plural - CsCDC.) CCDC - Consultant in Communicable Disease Control. (Plural - CsCDC.) -Sometimes also known as Consultants in Health Protection, or Consultants in Public Health (Environmental Health).+Sometimes also known as Consultants in Health Protection (usually used for non-medically qualified consultants), or Consultants in Public Health (Environmental Health). The post of CCDC was created by the Acheson Report, and is defined by English law. Although communicable disease control is a large part of a CCDC's work, a CCDC usually also prepares for and advises on non communicable environmental hazards. For this reason some prefer the title of Consultant in Health Protection; this title is less obviously meaningful, but does at least not appear to imply that the job only includes some aspects of what it actually involves. The post of CCDC was created by the Acheson Report, and is defined by English law. Although communicable disease control is a large part of a CCDC's work, a CCDC usually also prepares for and advises on non communicable environmental hazards. For this reason some prefer the title of Consultant in Health Protection; this title is less obviously meaningful, but does at least not appear to imply that the job only includes some aspects of what it actually involves. -In England, CsCDC were employed by Health Authorities until the implementation of "Shifting the Balance of Power". They them moved into the [http://www.hpa.org.uk Health Protection Agency], working in '''Health Protection Units (HPUs)'''; and then on 1 April [[2013]] into Public Health England, working in a '''Public Health England Centre (PHEC)''' - nothing to do with Father Ted - or a '''Health Protection Team'''+{{England|In England, CsCDC were employed by Health Authorities until the implementation of "Shifting the Balance of Power". They then moved into the [http://www.hpa.org.uk Health Protection Agency], working in '''Health Protection Units (HPUs)'''; and then on 1 April [[2013]] into Public Health England, working in a [[Public Health England|'''Public Health England Centre (PHEC)''']] - nothing to do with Father Ted - or a '''Health Protection Team'''. -There is a professional group primarily for CsCDC - the [http://www.phmeg.org.uk Public Health Medicine Environment Group (PHMEG)]. (Much of the content of this page was originally written for the PHMEG website.)+[https://www.gov.uk/health-protection-team '''Find your local health protection team in England'''.]}}  +   +   +A professional group primarily for CsCDC - the [http://www.phmeg.org.uk Public Health Medicine Environment Group (PHMEG)] changed its name to the Health Protection Society, and was wound up in 2017. (Some of the content of this page was originally written for the PHMEG website.) == History of the CCDC == == History of the CCDC == [...]



Measles

Tue, 12 Dec 2017 10:44:07 GMT

External links: ← Older revision Revision as of 10:44, 12 December 2017 Line 118: Line 118: == External links == == External links == -*[http://www.hpa.org.uk/infections/topics_az/measles/menu.htm HPA information on measles] or:+*[https://www.gov.uk/search?q=measles PHE information on measles], including: -:*[http://www.hpa.org.uk/infections/topics_az/measles/guidelines.htm Measles-related guidelines]+:*[https://www.gov.uk/government/publications/measles-outbreak patient leaflets (in many languages) with advice, produced for use when measles is circulating ](promulgated during a measles outbreak in late [[2017]]) -:*[http://www.hpa.org.uk/infections/topics_az/measles/gen_info.htm General information about measles]+:*[https://www.gov.uk/government/publications/viral-rash-in-pregnancy guidance on the management of rash diseases (including measles) in pregnancy] -:*[http://www.hpa.org.uk/infections/topics_az/measles/data.htm Epidemiological Data on measles]+ -:*[http://www.hpa.org.uk/infections/topics_az/vaccination/mmr.htm MMR information]+ *[http://www.health.gov.au/internet/wcms/publishing.nsf/Content/cda-cditech-measles.htm Guidelines for the control of measles outbreaks in Australia] - detailed guidelines in [[Wikipedia:Portable Document Format|pdf]] format can be downloaded from this page. *[http://www.health.gov.au/internet/wcms/publishing.nsf/Content/cda-cditech-measles.htm Guidelines for the control of measles outbreaks in Australia] - detailed guidelines in [[Wikipedia:Portable Document Format|pdf]] format can be downloaded from this page. {{refsec}} {{refsec}} [...]



Modern slavery

Mon, 11 Dec 2017 16:55:14 GMT

New page

{{stub}}
Modern slavery can refer to a variety of issues, including the trafficking of people to work as (for example) [[sex worker|sex workers]], agricultural workers or [http://www.independent.co.uk/news/uk/vietnam-nail-bar-workers-uk-modern-slavery-labour-exploitation-regulation-kevin-hyland-a7943011.html nail-bar technicians] ([https://www.thetimes.co.uk/article/exposed-scandal-of-nail-bar-slaves-jflnt9zfggq Sunday Times on nail bar slavery]).

Doctors may be required to [https://www.gov.uk/government/publications/human-trafficking-victims-referral-and-assessment-forms report suspected victims of modern slavery].

There has been some controversy over:
*Concerns that the Home Office might use reports under the modern slavery reporting arrangements to deport those reported.
*Alleged misuse of data to exaggerate the number suggest that all [[sex worker|sex workers]] are trafficked by anti-prostitution campaigners

==External Links==
*[[Wikipedia:Contemporary slavery|Wikipedia ''Contemporary slavery'' page]]
*[https://www.gov.uk/government/collections/modern-slavery Home Office page with links to information on modern slavery], including information on the duty to notify the Home Office (and the forms to do so); and to a [https://www.gov.uk/government/publications/modern-slavery-and-public-health PHE report on Modern slavery and public health]
*[https://www.antislavery.org/slavery-today/slavery-uk/ antislavery uk web page]
*[https://www.legislation.gov.uk/ukpga/2015/30/contents Modern Slavery Act 2015]

{{Refsec}}



Sexual health

Mon, 11 Dec 2017 16:49:04 GMT

Created page with "{{stub}} See also *sex worker"

New page

{{stub}}
See also
*[[sex worker]]



Sex worker

Mon, 11 Dec 2017 16:48:46 GMT

Created page with "{{stub}} See Wikipedia ''Sex worker'' page"

New page

{{stub}}
See [[Wikipedia:Sex worker|Wikipedia ''Sex worker'' page]]



Tick typhus

Mon, 11 Dec 2017 15:02:39 GMT

typo in etymology ← Older revision Revision as of 15:02, 11 December 2017 (One intermediate revision not shown)Line 3: Line 3: ==Old World== ==Old World== -The African form (also seen in the Mediterranean, South Asia and Australia) has the same sort of non-specific fever, headache and myalgia but there tends to be a bite lesion (a black ulcer, or ''tache noir'') which then develops into a more generalized rash.  A milder disease than Rocky Mountain Spotted Fever or louse borne typhus, unless complicated by other disease eg [[G6PD deficiency]]. Caused by ''[[Rickettsia conorii]]'' (African tick typhus, Boutonneuse fever, India tick typhus, Kenya tick typhus,Marseilles fever, Mediterranean tick fever), ''[[Rickettsia sibirica]]''  (North Asian tick fever and Siberian tick typhus)and ''[[Rickettsia australis]]'' (Queensland tick typhus)+{{EtymologyBox|boutonneuse is French for '''spotty''', which describes the associated rash.}} - +The African form (also seen in the Mediterranean, South Asia and Australia) has the same sort of non-specific fever, headache and myalgia but there tends to be a bite lesion (a black ulcer, or ''tache noir'') which then develops into a more generalized rash.  A milder disease than Rocky Mountain Spotted Fever or louse borne typhus, unless complicated by other disease eg [[G6PD deficiency]]. Caused by ''[[Rickettsia conorii]]'' (African tick typhus, Boutonneuse fever (fièvre boutonneuse), Indian tick typhus, Kenya tick typhus, Marseilles fever, Mediterranean tick fever), ''[[Rickettsia sibirica]]''  (North Asian tick fever and Siberian tick typhus)and ''[[Rickettsia australis]]'' (Queensland tick typhus) ==New World== ==New World== {{:Rocky Mountain spotted fever}} {{:Rocky Mountain spotted fever}} [...]



Boutonneuse fever

Mon, 11 Dec 2017 15:00:51 GMT

redirect

New page

#REDIRECT[[Tick typhus#Old World]]



Classical Hodgkin's lymphoma

Mon, 11 Dec 2017 14:57:04 GMT

redirect

New page

#REDIRECT[[Hodgkins lymphoma]]



Q-fever

Mon, 11 Dec 2017 14:56:03 GMT

redirect

New page

#REDIRECT[[Q fever]]



File:Ring granuloma 2.jpg

Mon, 11 Dec 2017 14:55:05 GMT

uploaded "[[File:Ring granuloma 2.jpg]]" Photomicrograph of a ring granuloma. {{ganfyd-licence}} Category: Photomicrographs




Ring granuloma

Mon, 11 Dec 2017 14:47:16 GMT

starter

New page

A histological pattern of granulomatous inflammation, also known as a ''fibrin ring granuloma''. Fibrin and epithelioid histiocytes encircle a lipid space.

[[Image:Ring granuloma 1.jpg|right|thumb|Ring granuloma.]]
[[Image:Ring granuloma 2.jpg|right|thumb|Ring granuloma.]]

The presence of ring granulomata in the bone marrow and liver are classically associated with [[Q-fever]] (Coxiella burnetii), but cutaneous involvement is also rarely described. However, ring granulomata are not pathognomonic for Q-fever and, at least in the liver, other causes include visceral [[leishmaniasis]], [[boutonneuse fever]], [[toxoplasmosis]], viral infections (EBV, CMV), [[classical Hodgkin's lymphoma]] and drug hypersensitivity.[https://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=1864592 Marazuela M, Moreno A, Yebra M, Cerezo E, Gómez-Gesto C, Vargas JA. Hepatic fibrin-ring granulomas: a clinicopathologic study of 23 patients. Human pathology. 1991 Jun; 22(6):607-613.](Print) ([http://dx.doi.org/10.1016/0046-8177(91)90240-p Link to article] – subscription may be required.)

{{refsec}}



Transcription intermediary factor 1

Mon, 11 Dec 2017 14:36:21 GMT

starter

New page

{{SubjectBox}}
Transcription intermediary factor 1, as the name suggests, is a family of proteins that appear to act as intermediary signalling proteins between activated nuclear receptors and their transcription targets.

Based on the structure, there are 3 members, α, β and γ.[https://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=10022127 Venturini L, You J, Stadler M, Galien R, Lallemand V, Koken MH, Mattei MG, Ganser A, Chambon P, Losson R, de Thé H. TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene. 1999 Feb; 18(5):1209-1217.](Print) ([http://dx.doi.org/10.1038/sj.onc.1202655 Link to article] – subscription may be required.)

Auto-antibodies against TIF1-γ show an association with cancer-associated myositis,[https://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=20501546 Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford, England). 2010 Sep; 49(9):1726-1733.](Print-Electronic) ([http://dx.doi.org/10.1093/rheumatology/keq153 Link to article] – subscription may be required.) regarded as a form of para-neoplastic [[dermatomyositis]].

{{refsec}}

[[Category: Auto-antibodies]]



TIF1

Mon, 11 Dec 2017 14:35:32 GMT

redirect

New page

#REDIRECT[[Transcription intermediary factor 1]]



Morbidity and mortality meeting

Mon, 11 Dec 2017 13:26:54 GMT

← Older revision Revision as of 13:26, 11 December 2017
Line 1: Line 1:
{{SubjectBox}}
{{SubjectBox}}
-
A morbidity and mortality meetings (aka morbidity and mortality conferences) were first established to review deaths as part of professional learning. They may also be used to provide assurance that patients are not dying as a consequence of unsafe clinical practices.[http://qualitysafety.bmj.com/content/21/7/576 Juliet Higginson, Rhiannon Walters, Naomi Fulop. '' Mortality and morbidity meetings: an untapped resource for improving the governance of patient safety?'' BMJ Quality and Safety  
+
Morbidity and mortality meetings (aka morbidity and mortality conferences) were first established to review deaths as part of professional learning. They may also be used to provide assurance that patients are not dying as a consequence of unsafe clinical practices.[http://qualitysafety.bmj.com/content/21/7/576 Juliet Higginson, Rhiannon Walters, Naomi Fulop. '' Mortality and morbidity meetings: an untapped resource for improving the governance of patient safety?'' BMJ Quality and Safety  
2012;21:576e585 doi: 10.1136/bmjqs-2011-000603.]
2012;21:576e585 doi: 10.1136/bmjqs-2011-000603.]



Veganism

Mon, 11 Dec 2017 13:25:04 GMT

Infants and Children: ← Older revision Revision as of 13:25, 11 December 2017 Line 20: Line 20: While case reports of adverse effects of vegan diets in infancy and childhood are reported (including long-term sequelae),[[Pubmed:2044594|Kühne T, Bubl R, Baumgartner R. Maternal vegan diet causing a serious infantile neurological disorder due to vitamin B12 deficiency. European journal of pediatrics. 1991;150:205-8.]][[Pubmed:16310594|Casella EB, Valente M, de Navarro JM, Kok F. Vitamin B12 deficiency in infancy as a cause of developmental regression. Brain development. 2005;27:592-4.]] ([http://dx.doi.org/10.1016/j.braindev.2005.02.005 Direct link] – subscription may be required.)[[Pubmed:9301352|von Schenck U, Bender-Götze C, Koletzko B. Persistence of neurological damage induced by dietary vitamin B-12 deficiency in infancy. Archives of disease in childhood. 1997;77:137-9.]][[Pubmed:15087959|Weiss R, Fogelman Y, Bennett M. Severe vitamin B12 deficiency in an infant associated with a maternal deficiency and a strict vegetarian diet. Journal of pediatric hematology/oncology 2004;26:270-1.]] these are often the result of parental ignorance or atypical beliefs[http://news.bbc.co.uk/1/hi/health/1542293.stm BBC report on an infant death following fruit-based diet] and adverse effects from poor diet are not confined to vegetarian or vegan diets (e.g. omnivorous parents weaning of babies exclusively onto cow's milk resulting in iron-deficiency anaemia). While case reports of adverse effects of vegan diets in infancy and childhood are reported (including long-term sequelae),[[Pubmed:2044594|Kühne T, Bubl R, Baumgartner R. Maternal vegan diet causing a serious infantile neurological disorder due to vitamin B12 deficiency. European journal of pediatrics. 1991;150:205-8.]][[Pubmed:16310594|Casella EB, Valente M, de Navarro JM, Kok F. Vitamin B12 deficiency in infancy as a cause of developmental regression. Brain development. 2005;27:592-4.]] ([http://dx.doi.org/10.1016/j.braindev.2005.02.005 Direct link] – subscription may be required.)[[Pubmed:9301352|von Schenck U, Bender-Götze C, Koletzko B. Persistence of neurological damage induced by dietary vitamin B-12 deficiency in infancy. Archives of disease in childhood. 1997;77:137-9.]][[Pubmed:15087959|Weiss R, Fogelman Y, Bennett M. Severe vitamin B12 deficiency in an infant associated with a maternal deficiency and a strict vegetarian diet. Journal of pediatric hematology/oncology 2004;26:270-1.]] these are often the result of parental ignorance or atypical beliefs[http://news.bbc.co.uk/1/hi/health/1542293.stm BBC report on an infant death following fruit-based diet] and adverse effects from poor diet are not confined to vegetarian or[...]



Dietician

Mon, 11 Dec 2017 13:24:02 GMT

Redirected page to Dietetics

New page

#redirect[[Dietetics]]